Dosing & Uses
Dosage Forms & Strengths
Neomycin/Polymyxin B/Gramicidin
ophthalmic solution
- (1.75 mg/10,000/0.025 mg)/1mL (10mL)
Treatment & Prevention of Ocular Infection &/or Inflammation
1-2 gtts q4-6hr for 7-10 days; if severe 2 gtts q1hr if necessary
Dosage Forms & Strengths
Neomycin/Polymyxin B/Gramicidin
ophthalmic solution
- (1.75 mg/10,000/0.025 mg)/1mL (10mL)
Treatment & Prevention of Ocular Infection &/or Inflammation
1-2 gtts q4-6hr for 7-10 days; if severe 2 gtts q1hr if necessary
Adverse Effects
Frequency Not Defined
Hypersensitivity
Itching, swelling, and conjunctival erythema
Local transient irritation
Vesicular and maculopapular dermatitis
Angioneurotic edema
Urticaria
Warnings
Contraindications
Aminglycoside/neomycin hypersensitivity; hypersensitivity to any product component
Cautions
Watch for NEOMYCIN ocular sensitivity
Defects in visual acuity may occur with prolonged use
Posterior subpapular cataract formation, and secondary ocular infections reported with prolonged use
Prolonged use may result in overgrowth of nonsusceptible organisms including fungi; if superinfection occurs, appropriate measures should be initiated
Bacterial resistance to may develop; if purulent discharge, inflammation, or pain becomes aggravated, patient should discontinue use and consult a physician
Allergic cross-reactions may occur which could prevent use of any or all of the following antibiotics for treatment of future infections: kanamycin, paromomycin, streptomycin, and possibly gentamicin
Pregnancy & Lactation
Pregnancy
Animal reproduction studies have not been conducted with neomycin sulfate, polymyxin B sulfate, or bacitracin; not known whether therapy can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity; treatment should be given to a pregnant woman only if clearly needed
Lactation
Not known whether drug is excreted in human milk; because many drugs are excreted in human milk, exercise caution when drug is administered to a nursing woman
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Inhibits bacterial cell wall synthesis by preventing the incorporation of amino acids and nucleotides into the cell wall
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
neomycin-polymyxin-gramicidin ophthalmic (eye) - | 1.75 mg-10,000 unit-0.025mg/mL drops | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.